Microorganisms for producing 1,4-butanediol and methods related thereto

Inventor: Wei Niu (Lincoln, NE)

Assignee: Genomatica, Inc.

C12N15/52 C12N9/0008 C12P7/16 C12P7/18 C12P7/42 C12Y102/99006 Y02E50/10

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 11,572,564
App. No.: 15/018,736
Granted: Feb 7, 2023
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The invention provides non-naturally occurring microbial organisms comprising a 1,4-butanediol (BDO), 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine pathway comprising at least one exogenous nucleic acid encoding a BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine pathway enzyme expressed in a sufficient amount to produce BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine and further optimized for expression of BDO. The invention additionally provides methods of using such microbial organisms to produce BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine.

Claims (3)

1. An engineered isolated carboxylic acid reductase (CAR) variant, comprising an amino acid sequence having at least 90% sequence identity to SEQ ID NO:101 and having an amino acid substitution selected from E16K; Q95L; L100M; A1011T; K823E; T941S; D198E; G446C; S392N; F699L; V883I; F467S; T987S; R12H; V295G; V295A; V295S; V295T; V295C; V295L; V295I; V295M; V295P; V295F; V295Y; V295W; V295D; V295E; V295N; V295Q; V295H; V295K; V295R; M296G; M296A; M296S; M296T; M296C; M296V; M296L; M296I; M296P; M296F; M296Y; M296W; M296D; M296E; M296N; M296Q; M296H; M296K; M296R; G297A; G297S; G297T; G297C; G297V; G297L; G297I; G297M; G297P; G297F; G297Y; G297W; G297D; G297E; G297N; G297Q; G297H; G297K; G297R; G391A; G391S; G391T; G391C; G391V; G391L; G391I; G391M; G391P; G391F; G391Y; G391W; G391D; G391E; G391N; G391Q; G391H; G391K; G391R; G421A; G421S; G421T; G421C; G421V; G421L; G421I G421M; G421P; G421F; G421Y; G421W; G421D; G421E; G421N; G421Q; G421H; G421K; G421R; D413G; D413A; D413S; D413T; D413C; D413V; D413L; D413I; D413M; D413P; D413F; D413Y; D413W; D413N; D413Q; D413H; D413K; D413R; G414A; G414S; G414T; G414C; G414V; G414L; G414I; G414M; G414P; G414F; G414Y; G414W; G414D; G414E; G414N; G414Q; G414H; G414K; G414R; Y415G; Y415A; Y415S; Y415T; Y415C; Y415V; Y415L; Y415I; Y415M; Y415P; Y415F; Y415W; Y415D; Y415E; Y415N; Y415Q; Y415H; Y415K; Y415R; G416A; G416S; G416T; G416C; G416V; G416L; G416I; G416M; G416P; G416F; G416Y; G416W; G416D; G416E; G416N; G416Q; G416H; G416K; G416R; S417G; S417A; S417T; S417C; S417V S417L; S417I; S417M; S417P; S417F; S417Y; S417W; S417D; S417E; S417N; S417Q; S417H; S417K; and S417R, corresponding to the amino acid positions of the sequence of SEQ ID NO:101, or combinations thereof, wherein said engineered isolated carboxylic acid reductase catalyzes the conversion of a carboxylic acid to its aldehyde, and wherein said engineered isolated CAR is not naturally-occurring.

2. An engineered isolated carboxylic acid reductase (CAR) variant comprising an amino acid sequence having at least 90% sequence identity to SEQ ID NO:101 and having an amino acid substitution at position V295, M296, G297, G391, G421, G414, Y415, G416 or 5417 corresponding to the amino acid positions of the sequence of SEQ ID NO:101, wherein said engineered isolated carboxylic acid reductase variant catalyzes the conversion of a carboxylic acid to its aldehyde, and wherein said engineered isolated CAR is not naturally-occurring.

3. An engineered isolated carboxylic acid reductase (CAR) variant comprising the amino acid sequence of SEQ ID NO:101 and having an amino acid substitution in SEQ ID NO:101 selected from the group consisting of E16K; Q95L; L100M; A1011T; K823E; T941S; H15Q; D198E; G446C; S392N; F699L; V883I; F467S; T987S; R12H; V295G; V295A; V295S; V295T; V295C; V295L; V295I; V295M; V295P; V295F; V295Y; V295W; V295D; V295E; V295N; V295Q; V295H; V295K; V295R; M296G; M296A; M296S; M296T; M296C; M296V; M296L; M296I; M296P; M296F; M296Y; M296W; M296D; M296E; M296N; M296Q; M296H; M296K; M296R; G297A; G297S; G297T; G297C; G297V; G297L; G297I; G297M; G297P; G297F; G297Y; G297W; G297D; G297E; G297N; G297Q; G297H; G297K; G297R; G391A; G391S; G391T; G391C; G391V; G391L; G391I; G391M; G391P; G391F; G391Y; G391W; G391D; G391E; G391N; G391Q; G391H; G391K; G391R; G421A; G421S; G421T; G421C; G421V; G421L; G421I G421M; G421P; G421F; G421Y; G421W; G421D; G421E; G421N; G421Q; G421H; G421K; G421R; D413G; D413A; D413S; D413T; D413C; D413V; D413L; D413I; D413M; D413P; D413F; D413Y; D413W; D413E; D413N; D413Q; D413H; D413K; D413R; G414A; G414S; G414T; G414C; G414V; G414L; G414I; G414M; G414P; G414F; G414Y; G414W; G414D; G414E; G414N; G414Q; G414H; G414K; G414R; Y415G; Y415A; Y415S; Y415T; Y415C; Y415V; Y415L; Y415I; Y415M; Y415P; Y415F; Y415W; Y415D; Y415E; Y415N; Y415Q; Y415H; Y415K; Y415R; G416A; G416S; G416T; G416C; G416V; G416L; G416I; G416M; G416P; G416F; G416Y; G416W; G416D; G416E; G416N; G416Q; G416H; G416K; G416R; S417G; S417A; S417T; S417C; S417V S417L; S417I; 5417M; S417P; S417F; S417Y; S417W; S417D; S417E; S417N; S417Q; S417H; S417K; and S417R, wherein said engineered isolated carboxylic acid reductase variant catalyzes the conversion of a carboxylic acid to its aldehyde, and wherein said engineered isolated CAR is not naturally-occurring.

Assignments (4)

SECURITY INTEREST Recorded Feb 10, 2026

From: GENOMATICA, INC.

To: AGAIN BIO APS

Reel/Frame 074708/0001 →

SECURITY INTEREST Recorded Dec 9, 2025

From: GENOMATICA, INC.

To: NOVO HOLDINGS A/S, AS COLLATERAL AGENT

Reel/Frame 073915/0027 →

SECURITY INTEREST Recorded Jun 2, 2025

From: GENOMATICA, INC.

To: OXFORD FINANCE LLC